Literature DB >> 27312390

The Role of Endoscopic Lavage in Recalcitrant Multidrug-Resistant Gram-Negative Ventriculitis Among Neurosurgical Patients.

Amandeep Kumar1, Deepak Agrawal2, Bhawani S Sharma2.   

Abstract

INTRODUCTION: Ventriculitis is a serious infection associated with high mortality even when both intravenous (IV) and intrathecal (IT) antibiotics are administered. Poor outcome in patients with ventriculitis indicates the need to be more aggressive in our attempts to expeditiously eradicate the infection. The purpose of this study was to evaluate the role of endoscopic lavage (EL) in patients with severe purulent ventriculitis, unresponsive to IV and IT antibiotics.
METHODS: All consecutive patients with severe ventriculitis caused by multidrug-resistant gram-negative bacteria, undergoing EL after failure of prolonged courses of IV and IT antibiotics, were included in the study. The outcome in all these patients was otherwise expected to be uniformly dismal.
RESULTS: There were 5 males and 2 females. The age range was one month to 45 years. All patients had frank intraventricular pus. Acinetobacter baumannii was the most common organism grown in cultures. Two patients had multiple bacterial growth in cerebrospinal fluid cultures. The duration of pre-EL IV/IT antibiotics ranged from 3 to 8 weeks. Microbiological cure was achieved in all (7/7) and clinical cure in 86% of patients (6/7). One patient died despite achieving cerebrospinal fluid sterilization 3 months later as a result of progressive white matter edema.
CONCLUSIONS: The addition of IT antibiotics has resulted in improved outcome in patients with ventriculitis; however, some patients continue to be unresponsive to antibiotics. EL can play a complementary role in eradicating such recalcitrant infections. EL should be considered in any patient with ventriculitis, if infection persists even after ∼7-10 days of IVand IT antibiotics.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endoscopic lavage; Multidrug-resistant gram-negative bacteria; Severe; Ventriculitis

Mesh:

Substances:

Year:  2016        PMID: 27312390     DOI: 10.1016/j.wneu.2016.06.022

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  6 in total

1.  Special Annual Issue on CNS Infections.

Authors:  Chandrashekhar Deopujari; Sandip Chatterjee; Dattatraya Muzumdar
Journal:  Childs Nerv Syst       Date:  2018-07-19       Impact factor: 1.475

Review 2.  Neuroendoscopic lavage for the treatment of pyogenic ventriculitis in children: personal series and review of the literature.

Authors:  Adalberto Ochoa; Romina Argañaraz; Beatriz Mantese
Journal:  Childs Nerv Syst       Date:  2021-11-13       Impact factor: 1.475

3.  A Clinical Study on the Use of Intraventricular Polymyxin B Supplemented by Continuous External Ventricular Drainage in the Treatment of Drug-Resistant Gram-Negative Bacilli Intracranial Infection.

Authors:  Hongwei Chen; Xiaochuan Guo; Dongcheng Xie; Xuanwei Dong; Jianxing Niu; Guoqiang Chen
Journal:  Infect Drug Resist       Date:  2020-08-24       Impact factor: 4.003

4.  Neuroendoscopic lavage for the treatment of CSF infection with hydrocephalus in children.

Authors:  C Gaderer; A Schaumann; M Schulz; U W Thomale
Journal:  Childs Nerv Syst       Date:  2018-07-11       Impact factor: 1.475

5.  Application of neuroendoscopic surgical techniques in the assessment and treatment of cerebral ventricular infection.

Authors:  Feng Guan; Wei-Cheng Peng; Hui Huang; Zu-Yuan Ren; Zhen-Yu Wang; Ji-Di Fu; Ying-Bin Li; Feng-Qi Cui; Bin Dai; Guang-Tong Zhu; Zhi-Yong Xiao; Bei-Bei Mao; Zhi-Qiang Hu
Journal:  Neural Regen Res       Date:  2019-12       Impact factor: 5.135

6.  Successful treatment of pyogenic ventriculitis caused by extensively drug-resistant Acinetobacter baumannii with multi-route tigecycline: A case report.

Authors:  Wei Li; Dan-Dong Li; Bo Yin; Dong-Dong Lin; Han-Song Sheng; Nu Zhang
Journal:  World J Clin Cases       Date:  2021-01-26       Impact factor: 1.337

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.